Here we demonstrated that oral administration of C.B effectively alleviated HFD-induced obesity and associated metabolic disorders, including glucose intolerance and hyperlipidemia, as well as systemic inflammation, as evidenced by reduced levels of LPS, TNF-α, and IL-1β. This evidence concerns the gene TNF and Other metabolic disease.